Oncopeptides AB

Oncopeptides AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company uses its proprietary peptide-drug conjugate (PDC) platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The first drug coming from PDC platform, PEPAXTO®(melphalan flufenamide), has been launched in the U.S., for the treatment of adult patients with relapsed or refractory multiple myeloma. Melphalan flufenamide is evaluated in a comprehensive clinical study program including the global phase 3 studies OCEAN and LIGHTHOUSE. Oncopeptides is developing several new compounds based on the PDC platform. The first one is expected to enter into clinical development in 2021.Oncopeptides has approximately 300 coworkers. The global Headquarters is based in Stockholm, Sweden and the U.S. Headquarters is situated in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on www.oncopeptides.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Additional patent protection for melflufen granted in the US until 2033

Wed, Apr 10, 2019 08:00 CET

Stockholm - 10 April 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that the US patent and trademark office has issued a notice that they intend to grant additional patents to Oncopeptides AB in the US. Oncopeptides has previously received the corresponding patent protection both in Japan and Europe.These patents (application numbers 14/438473 and 15/225323) protect, inter alia, the freeze-dried formulation. The patent protection extends to 2033. The freeze-dried preparation with melflufen is intended to be marketed at a future approval. “We have now approved formulation

First patient starts treatment with Ygalo® in Oncopeptides’ Phase II study BRIDGE in RRMM patients with renal impairment

Tue, Sep 18, 2018 11:30 CET

Stockholm – 18 September 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that the first patient has started treatment in the company's Phase II BRIDGE trial designed to study the Pharmacokinetics (PK), safety and efficacy of Ygalo® in combination with dexamethasone in multiple myeloma patients with renal impairment. Multiple myeloma commonly results in deteriorating renal function. This makes BRIDGE an important study to show treating physicians how Ygalo® can be used in Relapsed Refractory Multiple Myeloma (RRMM) patients with renal impairment.CEO comment "In

Oncopeptides present updated interim data from the ongoing HORIZON trial with Ygalo® at the 23rd Congress of The European Hematology Association (EHA)

Fri, Jun 15, 2018 09:30 CET

Stockholm – June 15, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they are presenting updated interim data with Ygalo® (melflufen) from the ongoing HORIZON trial at the 23rd EHA congress in Stockholm. The updated phase II-data show a clinical data set with an Overall Response Rate (ORR) of 32.1% and a Clinical Benefit Rate (CBR) of 39.3% with Ygalo® in relapsed/refractory multiple myeloma patients refractory to pomalidomide and/or daratumumab after failing on immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs).The data are presented in a poster that can

Preparing for commercialisation of Ygalo®

Wed, Apr 18, 2018 09:00 CET

Stockholm - 18 April 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) yesterday announced the notice for the AGM in which the Nomination Committee is proposing two new candidates for the Board of Directors. Per Wold-Olsen and Brian Stuglik will bring additional late-stage development and commercialisation experience to the company should the AGM vote in favour of the proposal. In conjunction with the AGM the proposal is furthermore that Alan Hulme will be stepping down as Chairman after eight successful years and handing over to Per Wold-Olsen as successor. Oncopeptides has over the last

Additional patent protection for Ygalo® granted in Japan until October 2033

Thu, Mar 08, 2018 08:00 CET

Stockholm - March 8, 2018 - Oncopeptides AB (Nasdaq Stockholm; ONCO) announced today that the Japanese Patent Office (JPO) recently issued a notice that they will grant an additional Japanese patent to Oncoeptides AB.The patent (application JP 2015-539556) covers inter alia the lyophilized formulation of Ygalo that is intended to be launched. The patent will expire in October 2033 "We are pleased to have received this patent notice which was in line with our expectations and it represents an important milestone for Ygalo’s future potential commercial value in this key territory. Last

There are no items matching the current filter

There are no more items matching the current filter

Share